Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 1, 2001
-
ARCHIVE Takepron Approved for Maintenance Therapy of Recurrent Reflux Esophagitis
January 1, 2001
-
ARCHIVE Business of Major Drugstore Chain Operators Continues to Expand
January 1, 2001
-
ARCHIVE JPMA to Work More Closely with Patients' Organizations
January 1, 2001
-
ARCHIVE Matsumotokiyoshi: Consolidated Half-year Sales Reach ¥115 Bil.
January 1, 2001
-
ARCHIVE Health Minister Stresses Need for Government to Support Genomic Research: 1st JPMA Forum
January 1, 2001
-
ARCHIVE Ten More Items to Be Allowed to Be Advertised by Medical Facilities
January 1, 2001
-
COLUMN 2001: A Bridge to the Future
January 1, 2001
-
ARCHIVE BUSINESS NEWS IN BRIEF
January 1, 2001
-
ARCHIVE Tsuruha Acquires Drug Tomato in Iwate
January 1, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 1, 2001
-
ARCHIVE Kaletra Included in NHI List
January 1, 2001
-
ARCHIVE Fukuda Denshi to Charge Customers for Maintenance Services
January 1, 2001
-
ARCHIVE Welfide Licenses Glaucoma Treatment to Senju
January 1, 2001
-
ARCHIVE NHI Price Listing of Relenza, Tamiflu No Sooner Than Mid February
January 1, 2001
-
ARCHIVE OTC NEWS IN BRIEF
January 1, 2001
-
ARCHIVE New Year's Greeting
January 1, 2001
-
ARCHIVE Ministries, Agencies to Be Reorganized
January 1, 2001
-
ARCHIVE Many Know about Anti-smoking Aids, But They Are Not Commonly Used: Survey
January 1, 2001
-
ARCHIVE The Year 2000 in RetrospectJapanese Drug Industry at the Mercy of Large Waves of Globalization
January 1, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…